Commonwealth Equity Services LLC Reduces Stake in Cencora, Inc. $COR

Commonwealth Equity Services LLC lowered its position in Cencora, Inc. (NYSE:COR) by 7.9% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 41,656 shares of the company’s stock after selling 3,580 shares during the period. Commonwealth Equity Services LLC’s holdings in Cencora were worth $13,019,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of the company. Atlantic Edge Private Wealth Management LLC increased its position in shares of Cencora by 70.0% during the 2nd quarter. Atlantic Edge Private Wealth Management LLC now owns 85 shares of the company’s stock valued at $25,000 after purchasing an additional 35 shares during the last quarter. Vermillion & White Wealth Management Group LLC grew its position in Cencora by 69.4% during the second quarter. Vermillion & White Wealth Management Group LLC now owns 105 shares of the company’s stock valued at $31,000 after buying an additional 43 shares during the period. Caldwell Trust Co purchased a new stake in Cencora during the second quarter valued at approximately $46,000. Salomon & Ludwin LLC raised its position in Cencora by 638.1% in the third quarter. Salomon & Ludwin LLC now owns 155 shares of the company’s stock worth $47,000 after acquiring an additional 134 shares during the period. Finally, Capital A Wealth Management LLC boosted its stake in shares of Cencora by 3,975.0% during the 2nd quarter. Capital A Wealth Management LLC now owns 163 shares of the company’s stock worth $49,000 after acquiring an additional 159 shares during the last quarter. Institutional investors own 97.52% of the company’s stock.

Cencora Price Performance

Shares of NYSE:COR opened at $335.73 on Friday. The company has a debt-to-equity ratio of 4.32, a quick ratio of 0.55 and a current ratio of 0.90. The firm has a fifty day moving average price of $349.89 and a 200 day moving average price of $318.27. Cencora, Inc. has a fifty-two week low of $233.61 and a fifty-two week high of $377.54. The firm has a market cap of $65.13 billion, a price-to-earnings ratio of 42.23, a P/E/G ratio of 1.60 and a beta of 0.66.

Cencora (NYSE:COR) last announced its quarterly earnings results on Wednesday, November 5th. The company reported $3.84 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.79 by $0.05. Cencora had a net margin of 0.48% and a return on equity of 227.15%. The company had revenue of $83.73 billion for the quarter, compared to the consensus estimate of $83.36 billion. During the same period in the previous year, the firm posted $3.34 EPS. Cencora’s revenue for the quarter was up 5.9% compared to the same quarter last year. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. As a group, sell-side analysts expect that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, December 1st. Investors of record on Friday, November 14th were paid a dividend of $0.60 per share. The ex-dividend date of this dividend was Friday, November 14th. This is a boost from Cencora’s previous quarterly dividend of $0.55. This represents a $2.40 dividend on an annualized basis and a yield of 0.7%. Cencora’s dividend payout ratio is currently 30.19%.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on COR shares. Robert W. Baird set a $392.00 target price on Cencora in a report on Tuesday, December 16th. JPMorgan Chase & Co. raised their price objective on Cencora from $344.00 to $417.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 11th. TD Cowen lifted their price objective on Cencora from $350.00 to $400.00 and gave the company a “buy” rating in a research report on Monday, November 10th. Evercore ISI set a $400.00 target price on shares of Cencora and gave the stock an “outperform” rating in a report on Thursday, November 6th. Finally, Wells Fargo & Company raised their target price on shares of Cencora from $354.00 to $405.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 11th. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $379.50.

Insiders Place Their Bets

In related news, EVP Elizabeth S. Campbell sold 3,351 shares of the business’s stock in a transaction on Friday, December 19th. The shares were sold at an average price of $342.10, for a total value of $1,146,377.10. Following the sale, the executive vice president owned 23,891 shares in the company, valued at approximately $8,173,111.10. The trade was a 12.30% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Silvana Battaglia sold 1,677 shares of the company’s stock in a transaction on Friday, December 19th. The shares were sold at an average price of $345.00, for a total transaction of $578,565.00. Following the sale, the executive vice president directly owned 18,796 shares in the company, valued at approximately $6,484,620. The trade was a 8.19% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 20,317 shares of company stock valued at $7,009,260 in the last quarter. 10.80% of the stock is currently owned by insiders.

Cencora Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.